HALF-LIFE AND DETECTION
How long Ipamorelin stays in your system: half-life versus detection.
Two different clocks — the ~2-hour pharmacokinetic half-life, and the much longer window in which anti-doping laboratories can still detect it.
The short answer
If you want to know how long does ipamorelin stay in your system, the honest answer is that there are two different clocks and they give very different numbers. The first is the pharmacokinetic half-life — how fast the body clears the drug from blood — and that is short, about 2 hours in humans. By that measure ipamorelin is mostly gone within a day. The second clock is detection: how long a testing laboratory can still find evidence of it, and that window is longer, because anti-doping labs look for the drug and its breakdown products in urine using extremely sensitive methods. So "it has a 2-hour half-life" and "a lab can detect it" are both true and are not in conflict. The half-life describes the drug's effect window; detection describes the testing window.
The pharmacokinetic half-life: about 2 hours
The human pharmacokinetics come from one well-conducted study in healthy men (eight per dose level, five intravenous infusions from 4.21 to 140.45 nmol/kg). It found dose-proportional kinetics with a terminal half-life of approximately 2 hours, clearance of 0.078 L/h/kg, and a steady-state volume of distribution of 0.22 L/kg [2]. "Terminal half-life" simply means the time for the blood concentration to fall by half during the elimination phase. The growth-hormone response it triggers is even briefer — a single discrete pulse peaking about 40 minutes after dosing, then subsiding [2]. So the active window is short: a fast rise, a single pulse, and clearance over the following hours. In rats, plasma clearance is roughly 5-fold lower than the older peptide GHRP-6, but the human figure is the one that answers the question.
The detection window is longer — and well mapped
Here is where the marketing assumption breaks down. A short half-life does not mean a short detection window, because laboratories are not measuring whether the drug is still pharmacologically active — they are looking for any trace of it or its metabolites. A comprehensive metabolism study identified at least three urinary ipamorelin metabolites, formed by enzymes that clip and modify the peptide, and built them into a database for doping control [11]. Detection methods then screen against that database: a direct-urine-injection method using liquid chromatography and ion-mobility mass spectrometry detects ipamorelin among 17 other prohibited small peptides at limits of detection of 50-500 pg/mL [9]. Because labs target the metabolites as well as the parent peptide, the realistic detection window outlasts the 2-hour half-life by a wide margin. The exact window depends on dose, route, and the specific assay — but the capability is established and the methods are published [9][11].
Why the two numbers diverge
The gap between a 2-hour half-life and a multi-fold-longer detection window is not a contradiction; it is the normal relationship between pharmacology and forensic testing. Half-life is a concentration measurement: how quickly the blood level halves [2]. Detection is a sensitivity measurement: the lowest amount an instrument can confirm, which for these methods reaches the picogram-per-milliliter range [9]. When an assay can confirm picogram traces and is tuned to find metabolites rather than just the intact drug, it will keep returning positives long after the parent compound has cleared to pharmacologically irrelevant levels [11]. For anyone subject to testing, the operative number is the detection window, not the half-life — and that is precisely the point the detection literature makes that the supplement marketing does not.
What this means for the appraisal
Reading the two clocks together sharpens the whole picture. The short half-life is part of why community protocols favor frequent, often pre-sleep, dosing — an inference from the pharmacokinetics, not a studied human schedule. The long, well-characterized detection window is why the common assumption that a research peptide evades testing is simply wrong for ipamorelin: it is on the World Anti-Doping Agency's prohibited list and the analytical methods to catch it are mature and published [9][11]. The regulatory side of that story is on the is ipamorelin fda approved page; the full evidence appraisal is in the Ipamorelin research.